Roll of Innate Immune Receptors (TLR) and their agonists in improving chemotherapy response in Triple Negative Breast Cancer Patients.
- Conditions
- Health Condition 1: Z191- Hormone sensitive malignancy status
- Registration Number
- CTRI/2020/03/023958
- Lead Sponsor
- Department of Biotechnology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Patient Selection:
a)Histopathologically proven TNBC
b)Age >18 years
c)Non-metastatic
d)No prior surgery or treatment for breast cancer or any other non-skin cancer
e)Undergoing surgery first
f)Planned for NACT fit to receive chemotherapy (Normal RFT LFT Hematological parameters 2D ECHO)
g)ECOG 0to1
h)Written, informed consent
Inclusion criteria for healthy female controls:
a)Age >18 years
b)Non-pregnant, non-lactating
c)No current or past or family history of malignancy
d)No h/o autoimmune disorder
e)Malignancy screen negative (oral, clinical breast and per vaginal examination SOS mammography, Visual Inspection with Acetic Acid (VIA) or PAP smear negative in last 3 yrs)
f)Written, informed consent
Exclusion Criteria:
a)Pregnant, lactating
b)Previous treatment for breast cancer or any other non-skin cancer
c)h/o autoimmune disorder
d)Viral markers (HBsAg, HCV, HIV) positive
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method